StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3053% below fair value
$0.74−0.08 (-10.20%)

Close on Nov 20, 2026Market cap $43.21MP/E 18.6Yield –

Spero Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Spero Therapeutics's free cash flow for the twelve months ending Dec 31, 2020 was -$86.03M. For fiscal 2020 it was -$86.03M. The highest annual figure on record is -$9.84M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2020Dec 31, 2020-$86.03M–
FY2019Dec 31, 2019-$50.33M–
FY2018Dec 31, 2018-$42.06M–
FY2017Dec 31, 2017-$39.14M–
FY2016Dec 31, 2016-$29.79M–
FY2015Dec 31, 2015-$9.84M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2021Sep 30, 2021-$4.95M–
Q4 FY2020Dec 31, 2020-$16.40M–
Q3 FY2020Sep 30, 2020-$21.32M–
Q2 FY2020Jun 30, 2020-$24.91M–
Q1 FY2020Mar 31, 2020-$23.41M–
Q4 FY2019Dec 31, 2019-$17.50M–
Q3 FY2019Sep 30, 2019-$9.68M–
Q2 FY2019Jun 30, 2019-$12.16M–
Q1 FY2019Mar 31, 2019-$11.01M–
Q4 FY2018Dec 31, 2018-$15.92M–
Q4 FY2016Dec 31, 2016-$9.47M–

More Spero Therapeutics figures

See a number that looks wrong?